Air Liquide's new LENOXeâ„¢ anaestheic drug is being presented at the European Congress of anaesthesiology on 9-12th June 2007 in Munich, Germany. It is due for commercial release by the end of 2007.
LENOXeâ„¢ is based on xenon (Xe), an air gas with very interesting anaesthetic properties. The LENOXeâ„¢ offering combines a gas, special packaging and the dispensing equipment necessary for its administration.
Along with being a very effective general anaesthetic agent, LENOXeâ„¢ has the lowest solubility among all inhalational anaesthetics, which permits rapid recovery at the end of surgery. LENOXeâ„¢ is not metabolised by the human body, thus improving organ preservation. Moreover, one of the major advantages of LENOXeâ„¢, and certainly the most promising, is that it maintains cardiovascular function during anaesthesia by its ability to keep the blood pressure relatively stable and its absence of effect on contraction of the heart.
Jean-Marc de Royere, senior vice-president in charge of the Healthcare World Business Line of Air Liquide, declared, $quot;The launch of LENOXeTM in the European market marks the first step in introducing our ‘therapeutic gases’ program. We are very excited by this outcome that demonstrates our innovation and opens up a promising new field in healthcare.$quot;
... to continue reading you must be subscribed
